The Food and Drug Administration delayed its decision on Amarin Corp.'s (Nasdaq: AMRN) supplemental new drug application as it continues to consider reinstating the ANCHOR Special Protocol Assessment agreement for Vascepa. The stock price surged 41 cents to close at $2.00.
FDA May Reinstate Amarin's Special Protocol Assessment
December 20, 2013 at 16:31 PM EST
